

YUKON TERRITORY
CUMULATIVE ANTI BIOGRAM FOR JANUARY 1, 2020 – DECEMBER 31, 2020

GRAM-NEGATIVES	N	PERCENTAGE OF ISOLATES SUSCEPTIBLE TO:										
		AMPICILLIN	CEFAZOLIN §	CEFTAZIDIME	CEFTRIAXONE	CIPROFLOXACIN	GENTAMICIN	MEROPENEM	NITROFURANTOIN*	PIP/TAZOBACTAM	TOBRAMYCIN	TRIMETH/SULFA
<i>Enterobacter cloacae</i> [1]	35	R	R	-	62	75	93	97	31	70	90	77
<i>Escherichia coli</i> [1]	964	62	91	-	95	72	97	100	96	95	98	76
<i>Klebsiella oxytoca</i> [1]	30	R	47	-	85	88	93	98	80	86	91	73
<i>Klebsiella pneumoniae</i> [1]	92	R	89	-	97	87	97	99	27	96	96	91
<i>Pseudomonas aeruginosa</i>	67	R	R	100	-	87	99	98	R	100	100	R

Note 1: Organisms producing AmpC β -lactamases may develop resistance during prolonged therapy with 3rd cephalosporins

Note 2: 3.8% of *E. coli* and 2.2% of *K. pneumoniae* isolates produce Extended Spectrum β -lactamases (ESBL)

GRAM-POSITIVES	N	PERCENTAGE OF ISOLATES SUSCEPTIBLE TO:										
		AMPICILLIN	CEFTRIAXONE	CLINDAMYCIN	CLOXACILLIN	DAPTOMYCIN	ERYTHROMYCIN	LINEZOLID	PENICILLIN	TETRACYCLINE	TRIMETH/SULFA	VANCOMYCIN
<i>Staphylococcus aureus</i> (MSSA)	434	-	-	91	100	-	71	100	10	97	92	100
MRSA	94	R	R	94	R	-	33	100	R	84	85	100
<i>Staphylococcus lugdunensis</i>	40	-	-	90	90	-	88	100	37	98	100	100
Coagulase-negative staphylococci	45	-	-	69	44	-	32	100	2	-	-	100
<i>Enterococcus faecalis</i>	138	100	R	R	R	-	R	98	-	-	-	100
<i>Streptococcus pyogenes</i> ^a	482	-	-	<	-	-	<	-	100	-	-	100

LEGEND:

- N Number of isolates tested
- R This organism is inherently resistant to this antibiotic
- < Insufficient number of isolates tested, cumulative data not available
- * Urine isolates only
- § Cefazolin predicts for oral cephalosporins in patients with uncomplicated UTI
- Antibiotic not tested and/or not indicated
- ^a Penicillin is the antibiotic of choice for *S. pyogenes*